DCOY NASDAQ
Decoy Therapeutics Inc.
1W: -42.7%
1M: -40.6%
3M: -75.6%
YTD: -77.4%
$1.77
-0.09 (-4.58%)
Weekly Expected Move ±24.8%
$1
$1
$2
$2
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$0.9M
52W Range1.61-55.92
Volume251,309
Avg Volume1,686,545
Beta0.56
Dividend—
Analyst Ratings
Company Info
CEOFrederick E. Pierce
Employees11
SectorHealthcare
IndustryBiotechnology
IPO Date2015-01-29
Websitedecoytx.com
2450 Holcombe Blvd
Houston, TX 77021
US
Houston, TX 77021
US
1 617-314-9333
About Decoy Therapeutics Inc.
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
Latest News
Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors
12 Health Care Stocks Moving In Thursday's Intraday Session
Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Hibner Barbara Louis | A-Award | 4,216 | — | 2026-08-31 |
| HANISH ARNOLD C | A-Award | 3,000 | — | 2026-08-31 |
| Burleson Tess | A-Award | 2,000 | — | 2026-08-31 |
| McVicar William K. | A-Award | 3,000 | — | 2026-08-31 |
| Gauthier Patricia G. | A-Award | 2,000 | — | 2026-08-31 |